LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on Latin America, announced today that its Venezuelan subsidiary, LATAMEDAI VE, has entered into a memorandum of understanding (MOU) with FARMASER to develop a customized artificial intelligence and automation platform designed to support the pharmacy chain’s current operations and planned expansion.
Under the MOU, the parties will collaborate on designing, adapting, testing, and evaluating a software platform tailored to FARMASER’s operational requirements. This includes defining technical and operational specifications, adapting the software to pharmacy workflows, and establishing a phased development and testing process. The partnership also contemplates integrating LataMed AI’s CardioAI, PulmoAI, and NeuroAI models across FARMASER’s three existing locations and up to 15 planned additional sites, alongside e-commerce, prescription management, customer service, inventory planning, and business analytics functions.
The integration of these AI models is intended to support access to cardiovascular, pulmonary, and neurological health information and related digital health services, subject to continued development, testing, regulatory requirements, and clinical protocols. LataMed AI emphasized that any AI-supported functionality would assist administrative and healthcare workflows, not replace the judgment of pharmacists or medical professionals.
The companies are also evaluating an annual software licensing or subscription model for commercial implementation, though scope, timing, pricing, and other terms remain subject to successful development and testing, as well as definitive documentation.
“This memorandum of understanding represents an opportunity to apply our technology within an important part of the healthcare delivery ecosystem,” said Dr. Kevin Rodan Levy, CEO of LataMed AI Corp. “Pharmacies play a central role in connecting patients with medications, healthcare products, and related services. Our objective is to work with FARMASER to develop a platform that supports its current operations and planned expansion while evaluating the integration of our AI-supported healthcare technologies across its pharmacy network.”
Management believes the proposed collaboration aligns with LataMed AI’s broader strategy of building an integrated healthcare ecosystem connecting patients, healthcare professionals, pharmacies, insurers, and payment providers. The FARMASER platform could represent an enterprise application of the company’s technology beyond patient-facing telemedicine, potentially adaptable to other healthcare organizations throughout Latin America.
The MOU establishes a framework for cooperation but does not guarantee successful completion or commercial deployment, integration of AI technologies, execution of a definitive licensing agreement, opening of additional FARMASER locations, or revenue generation. For additional information, visit https://latamed.ai or review SEC filings at www.sec.gov.
This partnership underscores LataMed AI’s commitment to developing digital health infrastructure in Latin America, leveraging AI to improve access to healthcare services. The proposed platform aims to streamline pharmacy operations while potentially integrating advanced health information tools, marking a step toward a more connected healthcare ecosystem in the region.
